About Dr. Wang Jiyao
Dr. Wang Jiyao (王吉耀) is one of China's most eminent gastroenterologists and a nationally recognized authority on inflammatory bowel disease, liver disease, and advanced endoscopy. She serves as Director of the Department of Gastroenterology at Zhongshan Hospital, affiliated with Fudan University, and holds the title of Chief Physician and Professor.
Over a career spanning more than three decades, Dr. Wang has established Zhongshan Hospital's Gastroenterology Department as one of the premier digestive disease centers in China. She is particularly renowned for her expertise in inflammatory bowel disease (IBD), autoimmune liver disease, and non-alcoholic fatty liver disease (NAFLD) — areas where her contributions have shaped national clinical guidelines and influenced gastroenterology practice across China.
International patients with IBD, liver disease, or complex gastrointestinal conditions consistently identify Dr. Wang as one of China's top gastroenterologists for both primary treatment and expert second opinions.
Professional Positions and Affiliations
- Director, Department of Gastroenterology, Zhongshan Hospital, Fudan University
- Chairwoman, IBD Committee, Chinese Society of Gastroenterology
- Vice Chairwoman, Chinese Society of Gastroenterology
- Editorial Board Member: Journal of Crohn's and Colitis, Inflammatory Bowel Diseases, Journal of Gastroenterology and Hepatology
- Member, European Crohn's and Colitis Organisation (ECCO)
- Member, Asian Pacific Association of Gastroenterology (APAGE)
Specialties and Clinical Expertise
- Inflammatory Bowel Disease (IBD) — Crohn's disease and ulcerative colitis; biologic therapy (anti-TNF, vedolizumab, ustekinumab, risankizumab, ozanimod); JAK inhibitor therapy (tofacitinib, upadacitinib); treat-to-target protocols with endoscopic mucosal healing as primary endpoint; therapeutic drug monitoring (TDM) and dose optimization
- Autoimmune Liver Disease — autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and overlap syndromes; immunosuppressive therapy and obeticholic acid for PBC
- Non-Alcoholic Fatty Liver Disease (NAFLD/NASH) — metabolic risk stratification, liver biopsy interpretation, fibrosis staging, and emerging pharmacotherapy
- Advanced Endoscopy — colonoscopy with chromoendoscopy for IBD dysplasia surveillance; endoscopic balloon dilation for Crohn's strictures; endoscopic mucosal resection (EMR) for colorectal polyps
- Gastrointestinal Motility Disorders — irritable bowel syndrome (IBS), functional dyspepsia, and gastroparesis; Rome IV-based diagnosis and management
- Celiac Disease and Malabsorption — diagnosis and dietary management; particularly relevant for international patients from Western countries
- Microscopic Colitis — collagenous and lymphocytic colitis; budesonide therapy
Academic and Research Contributions
Dr. Wang Jiyao has published over 180 peer-reviewed papers in leading international gastroenterology journals, with a particular focus on IBD epidemiology in China, the optimization of biologic therapy for Crohn's disease and ulcerative colitis, and the natural history of autoimmune liver disease in Chinese patients. Her landmark epidemiological research demonstrating the rapid rise of IBD incidence in China — mirroring the pattern seen in Western countries decades earlier — has been widely cited and has contributed to international understanding of IBD as a global disease.
She chairs the IBD Committee of the Chinese Society of Gastroenterology and has been a lead author on China's national IBD management guidelines. She is a regular invited speaker at ECCO (European Crohn's and Colitis Organisation), DDW (Digestive Disease Week), and APAGE annual congresses.
Why International Patients Choose Dr. Wang Jiyao
- China's leading IBD specialist — Chairwoman of China's national IBD committee and national guideline author
- Full biologic and small molecule therapy access — all approved biologics and JAK inhibitors with therapeutic drug monitoring
- Autoimmune liver disease expertise — AIH, PBC, PSC, and overlap syndromes
- ECCO member — aligned with European IBD management standards
- Celiac disease expertise — particularly relevant for Western expatriates and international patients
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Zhongshan Hospital, 180 Fenglin Road, Xuhui District, Shanghai
- Appointment Lead Time: 2″4 weeks; urgent cases expedited through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Pre-consultation: Overseas colonoscopy reports, biopsy results, and prior treatment records reviewed remotely through CMCS
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking gastroenterology care with Dr. Wang Jiyao at Zhongshan Hospital. Our services include priority appointment booking, medical record translation, remote pre-consultation review, on-site interpretation, accommodation coordination, insurance liaison, and post-treatment follow-up with your home country gastroenterologist.
📧 Contact us: contract@medicalsh.com
💬 WeChat: gezhanglao
🌐 medicalsh.com
0 条评论